211 results
To assess the impact of SABR, compared to standard of care treatment, on overall survival, oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10 metastatic lesions.
AimThe MAPS study aims to unravel the immune composition of the human peritoneal cavity and the tumor immune environment in peritoneal metastasized gastric and colorectal cancer. The overarching aim is to find new targets for immunotherapy for this…
1. To determine the feasibility of SGM-101 for intraoperative imaging of colorectal lung metastases - Concordance between fluorescent signal and tumor status of resected tissue2. To define the optimal dose of SGM-101 for intraoperative imaging of…
The primary objective is to compare efficacy of MWA to the efficacy of SBRT with regards to the primary endpoint (local tumour progression free survival at 1 year [1-year LTPFS]) in patients with unresectable CRLM (3 - 5 cm) that are unsuitable for…
This study has been transitioned to CTIS with ID 2023-503291-24-00 check the CTIS register for the current data. Main objective:Dose Escalation Part:• To assess the safety and tolerability of DF1001 monotherapy, and to determine the Maximum…
Primary Objectives:• To compare Blinded Independent Committee for Radiology (BICR)-assessed objective response rate (ORR) in participants of tissue Tumor Mutational Burden-High (tTMB-H) treated with nivolumab combined with ipilimumab • To compare…
This study has been transitioned to CTIS with ID 2024-511134-12-00 check the CTIS register for the current data. The objective of this trial is to evaluate progression-free survival in synchronous oligometastatic NSCLC patients treated with…
We propose to use an alternative superparamagnetic tracer containing ironoxide, which can be detected with MRI and with a magnetic probe. The spatial resolution of MRI is superior to gamma camera detection. Moreover, there is no radiation exposure…
To evaluate if navigation assistance results in more successful localization and removal of extra-regional abdominal lymph nodes compared to standard surgery. Extra regional lymph nodes are defined as suspect target lymph nodes outside the standard…
The FURTHER study aims to evaluate the effectiveness and cost-effectiveness of MR-HIFU (alone or in combination with EBRT) compared to EBRT alone, the standard-of-care, as a palliative treatment option to relieve CIBP.
The primary objective of the clinical performance study is to demonstrate the clinical performance of VENTANA PD-L1 (SP263) CDx Assay in terms of its ability to identify NSCLC patients who may benefit from treatment with volrustomig plus…
The primary aim of this study is to determine the added value of third look DLS to detect PM at a clinically occult stage following a negative second look DLS.
To develop a model system and infrastructure to individualize the treatment of patients with advanced pancreatic adenocarcinoma. Additionally, we aim to identify predictors of therapy (non)response.
To determine if the incidence of adverse local events (local failure or radionecrosis) can be reduced with more than 20% using fSRT versus SRT in one or three fractions.
This study has been transitioned to CTIS with ID 2023-509457-31-00 check the CTIS register for the current data. To determine the immune-related progression free survival (irPFS) rate at 21 weeks and objective response rate (irORR) at 30 weeks in…
The aim of this study is to investigate in patients with metastatic HER2 positive or HER2-low breast cancer whether a PET scan with a new HER2 tracer ([89Zr] DFO*trastuzumab) accurately depicts all abnormalities and whether ultimately this HER2 PET…
To study the effect of immune modulating therapies, including anti-CTLA4, anti-PD-1, anti-PD-L1checkpoint inhibitors, and TIL therapy, on the composition and activation of systemic and local immunity, with an emphasis on the size and diversity of…
This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7502175 as a single…
This clinical performance study will evaluate the effectiveness of the CLDN18.2 (SP455) Clinical Trial Assay in identifying CLDN18.2 status in Adult Participants with Advanced or Metastatic Solid Tumours treated with AZD5863.